Can you provide some background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations that have been investigated and are likely to be approved?

Can you provide some background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations that have been investigated and are likely to be approved?

Can you provide some background, including dosing and units of each component, for the two fixed ratio, combination, insulin-plus-GLP-1 receptor agonist formulations that have been investigated and are likely to be approved?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine University of California San Diego, California Chief Medical Officer National Research Institute Los Angeles, California